Open Access Journal
QUALIS
B1
2021-2024
quadriênio
Open Access Journal
B1
2021-2024
quadriênio
Acute Lymphoblastic Leukemia (ALL) is a neoplasm characterized by intense cellular proliferation and low differentiation of immature lymphocytes. It accounts for approximately 80% of childhood leukemia cases, with the highest incidence among children aged two to five years. Conventional treatment involves chemotherapy, radiotherapy, and allogeneic hematopoietic stem cell transplantation. However, CAR-T cell therapy has emerged as an innovative strategy, based on the genetic modification of T lymphocytes to express chimeric antigen receptors. This study, an integrative review conducted in PubMed and ScienceDirect databases (2020–2025), synthesizes evidence on the application of CAR-T immunotherapy in refractory or relapsed ALL. Results indicate complete remission rates ranging from 67% to 90%, with negative minimal residual disease. Tisagenlecleucel demonstrated consistent responses in pediatric and young adult patients, while therapies such as KTE-X19 and CTL019 showed durable efficacy in adults. Platforms like AUTO1 and AUTO3 exhibited favorable safety profiles, with lower incidence of toxicities. Despite adverse events such as cytokine release syndrome and neurotoxicity, treatment efficacy remains uncompromised, highlighting the need for automation strategies to enhance CAR-T cell persistence.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Natali Adrielly Gusmão da Silva, Mirella de Sousa Albuquerque, Michele Vieira de Carvalho, Marina Gomes Pessoa Baptista, José Roberto Pimentel